The anti-oestrogen ICI 182,780, but not tamoxifen, inhibits the growth of MCF-7 breast cancer cells refractory to long-term oestrogen deprivation through down-regulation of oestrogen receptor and IGF signalling

Endocrine-Related Cancer

Volumn 12, Issue 4, 2005, Pages 1017-1036

  Martin, L A ^a   Pancholi, S ^a   Chan, C M W ^a   Farmer, I ^a   Kimberley, C ^a   Dowsett, M ^a   Johnston, S R D ^b  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b ROYAL MARSDEN HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ESTRADIOL; ESTROGEN RECEPTOR; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; FULVESTRANT; INSULIN; INSULIN RECEPTOR SUBSTRATE 2; SOMATOMEDIN; SOMATOMEDIN C RECEPTOR; TAMOXIFEN;

APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL; CANCER INHIBITION; CELL GROWTH; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOWN REGULATION; GENE EXPRESSION REGULATION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SIGNAL TRANSDUCTION;

ANTINEOPLASTIC AGENTS, HORMONAL; APOPTOSIS; BREAST NEOPLASMS; CELL PROLIFERATION; DOWN-REGULATION; ESTRADIOL; ESTROGEN ANTAGONISTS; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; ESTROGENS; FEMALE; HUMANS; INSULIN; INSULIN ANTAGONISTS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; PHOSPHOPROTEINS; RECEPTOR, IGF TYPE 1; TAMOXIFEN; TRANSCRIPTION, GENETIC;

EID: 29144494969     PISSN: 13510088     EISSN: None     Source Type: Journal    
DOI: 10.1677/erc.1.00905     Document Type: Article

References (54)

1. Ando S, Panno M-L, Salerno M, Sisci D, Mauro L, Lanzino M & Surmacz E 1998 Role of IRS-1 signaling in insulin-induced modulation of estrogen receptors in breast cancer cells. Biochemical and Biophysical Research Communications 253 315-319.
2. ATAC Trialists' Group 2002 Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet 359 2131-2139.
3. Bunone G, Briand PA, Miksicek RJ & Picard D 1996 Activation of the unliganded estrogen receptor by EGF involves the MAP kinase pathway and direct phosphorylation. EMBO Journal 15 2174-2183.
4. Buzdar AU 2003 Advances in endocrine treatments for postmenopausal women with metastatic and early breast cancer. Oncologist 8 335-341.
5. Buzdar A & Howell A 2001 Advances in aromatase inhibition: clinical efficacy and tolerability in the treatment of breast cancer. Clinical Cancer Research 7 2620-2635.
6. Buzdar A, Jonat W, Howell A, Jones SE, Blomqvist CP, Vogel CL, Eiermann W, Wolter JM, Steinberg M, Webster A & Lee D 1998 Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma: results of a survival update based on a combined analysis of data from two mature phase III trials. Cancer 83 1142-1152.
7. Chan CMW, Martin L-A, Johnston SRD, Ali S & Dowsett M 2002 Molecular changes associated with acquisition of estrogen hypersensitivity in MCF-7 breast cancer cells on long-term estrogen deprivation. Journal of Steroid Biochemistry and Molecular Biology 81 333-341.
8. Chan TW, Pollak M & Huynh H 2001 Inhibition of insulin-like growth factor signaling pathways in mammary gland by pure antiestrogen ICI 182,780. Clinical Cancer Research 7 2545-2554.
9. Coutts AS & Murphy LC 1998 Elevated mitogen-activated protein kinase activity in estrogen-nonresponsive human breast cancer cells. Cancer Research 58 4071-4074.
10. Darbre PD, Yates J, Curtis S & King RJB 1983 Effect of estradiol on human breast cancer cells in culture. Cancer Research 43 349-354.
11. Daws MR, Westley BR & May FEB Paradoxical effects of overexpression of the type-1 insulin-like growth factor (IGF) receptor on the responsiveness of human breast cancer cells to IGFs and estradiol. Endocrinology 137 1177-1186.
12. DeNardo DG, Kim HT, Hilsenbeck S, Cuba V, Tsimelzon A & Brown PH 2005 Global gene expression analysis of estrogen receptor transcription factor cross talk in breast cancer: identification of estrogen-induced/activator protein-1-dependent genes. Molecular Endocrinology 19 362-378.
13. Dombernowsky P, Smith IE, Falkson G, Leonard R, Panasci L, Bellmunt J, Bezwoda W, Gardin G, Gudgeon A, Morgan M et al. 1998 Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomised trial showing a dose-effect and improved efficacy and tolerability compared with megestrol acetate. Journal of Clinical Oncology 16 453-461.
14. Dowsett M, Goss PE, Powles TJ, Hutchinson G, Brodie AM, Jeffcoate SL & Coombes RC 1987 Use of the aromatase inhibitor 4-hydroxyandrostenedione in postmenopausal breast cancer: optimization of therapeutic dose and route. Cancer Research 47 1957-1961.
15. Geisler J, Haynes B, Anker G, Dowsett M & Lonning PE 2002 Influence of letrozole and anastrozole on total body aromatization and plasma estrogen levels in postmenopausal breast cancer patients evaluated in a randomized, cross-over study. Journal of Clinical Oncology 20 751-757.
16. Guvakova MA & Surmacz E 1997 Tamoxifen interferes with the insulin-like growth factor I receptor (IGF-1R) signaling pathway in breast cancer cells. Cancer Research 57 2606-2610.
17. Huynh H, Nickerson T, Pollak M & Yang X 1996a Regulation of insulin-like growth factor I receptor expression by the pure antiestrogen ICI 182780. Clinical Cancer Research 2 2037-2042.
18. Huynh HT, Yang X & Pollack M 1996b Estradiol and anti-estrogens regulate a growth inhibitory insulin-like growth factor binding protein 3 autocrine loop in human breast cancer cells. Journal of Biological Chemistry 271 1016-1021.
19. Ishikawa T, Takano K, Yasufuku-Takano J, Fujita T, Igarashi T, Miura M & Hata K 2001 Estrogenic impurities in labware. Nature Biotechnology 19 812.
20. Jackson JG, White MF & Yee D 1998 Insulin receptor substrate-1 is the predominant signaling molecule activated by insulin-like growth factor-1, insulin, and interleukin-4 in estrogen receptor positive human breast cancer cells. Journal of Biological Chemistry 273 9994-10003.
21. Jeng M-H, Shupnik MA, Bender TP, Westin EH, Bandyopadhyay D, Kumar R, Masamura S & Santen RJ 1998 Estrogen receptor expression and function in long-term estrogen-deprived human breast cancer cells. Endocrinology 139 4164-4174.
22. Johnston SR & Dowsett M 2003 Aromatase inhibitors for breast cancer: lessons from the laboratory. Nature Reviews in Cancer 3 821-831.
23. Kahlert S, Nuedling S, van Eickels M, Vetter H, Meyer R & Grohe C 2000 Estrogen receptor α rapidly activates the IGF-1 receptor pathway. Journal of Biological Chemistry 275 18447-18453.
24. Lee AV, Jackson JG, Gooch JL, Hilsenbeck SG, Coronado-Heinsohn E, Osborne CK & Yee D 1999 Enhancement of insulin-like growth factor signaling in human breast cancer: estrogen regulation of insulin receptor substrate-1 expression in vitro and in vivo. Molecular Endocrinology 13 787-796.
25. Lewis JS, Osipo C, Meeke K & Jordan VC 2005 Estrogen-induced apoptosis in a breast cancer model resistant to long-term estrogen withdrawal. Journal of Steroid Biochemistry and Molecular Biology 94 131-141.
26. Liu H, Lee ES, Gajdos C, Pearce ST, Chen B, Osipo C, Loweth J, McKian K, De Los Reyes A, Wing L & Jordan VC 2003 Apoptotic action of 17beta-estradiol in raloxifene-resistant MCF-7 cells in vitro and in vivo. Journal of the National Cancer Institute 95 1586-1597.
27. McClelland RA, Gee JMW, Francis AB, Robertson JF, Blamey RW, Wakeling AE & Nicholson RI 1996 Short-term effects of pure antiestrogen ICI 182780 treatment on estrogen receptor, epidermal growth factor receptor and transforming growth factor-alpha protein expression in human breast cancer. European Journal of Cancer 32A 413-416.
28. Marquez DC & Pietras RJ 2001 Membrane-associated binding sites for estrogen contribute to growth regulation of human breast cancer cells. Oncogene 20 5420-5430.
29. Martin LA, Farmer I, Johnston SR, Ali S, Marshall C & Dowsett M 2003 Enhanced estrogen receptor (ER) alpha, ERBB2, and MAPK signal transduction pathways operate during the adaptation of MCF-7 cells to long term estrogen deprivation. Journal of Biological Chemistry 278 30458-30468.
30. Masamura S, Santner SJ, Heitjan DF & Santen RJ 1995 Estrogen deprivation causes estradiol hypersensitivity in human breast cancer cells. Journal of Clinical Endocrinology and Metabolism 80 2918-2925.
31. Molloy CA, May FEB & Westley BR 2000 Insulin receptor substrate-1 expression is regulated by estrogen in the MCF-7 human breast cancer cell line. Journal of Biological Chemistry 275 12565-12571.
32. Mouridsen H, Gershanovich M, Sun Y, Pérez-Carrión R, Boni C, Monnier A, Apffelstaedt J, Smith R, Sleeboom HP, Jänicke F et al. 2001 Superior efficacy of letrozole (femara) versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group. Journal of Clinical Oncology 19 2596-2606.
33. Nabholtz JM, Buzdar A, Pollak M, Harwin W, Burton G, Mangalik A, Steinberg M, Webster A & von Euler M 2000 Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicentre randomised trial. Journal of Clinical Oncology 18 3758-3767.
34. Nicholson RI, McCelland RA, Robertson JF & Gee JM 1999 Involvement of steroid hormone and growth factor cross-talk in endocrine response in breast cancer. Endocrine-Related Cancer 6 373-387.
35. Oesterreich S, Zhang P, Guler RL, Sun X, Curran EM, Welshons WV, Osborne CK & Lee AV 2001 Re-expression of estrogen receptor a in estrogen receptor a-negative MCF-7 cells restores both estrogen and insulin-like growth factor mediated signaling and growth. Cancer Research 61 5771-5777.
36. Osipo C, Gajdos C, Lui H, Chen B & Jordan VC 2003 Paradoxical action of fluvistrant in estradiol induced regression of tamoxifen stimulated breast cancer. Journal of the National Cancer Institute 95 1597-1608.
37. Powell CE, Soto AM & Sonnenschein C 2001 Identification and characterization of membrane estrogen receptor from MCF-7 estrogen-target cells. Journal of Steroid Biochemistry and Molecular Biology 77 97-108.
38. Rajah TT, Dunn ST & Pento JT 1996 The influence of anti-estrogens on pS2 and cathepsin D mRNA induction in MCF-7 breast cancer cells. Anticancer Research 16 837-842.
39. Salerno M, Sisci D, Mauro L, Guvakova MA, Ando S & Surmacz E 1999 Insulin receptor substrate 1 is a target for the pure anti-estrogen ICI 182780 in breast cancer cells. International Journal of Cancer 81 299-304.
40. Santen R, Jeng M-H, Wang J-P, Song R, Masamura S, McPherson R, Santner S, Yue W & Shim WS 2001 Adaptive hypersensitivity to estradiol: potential mechanism for secondary hormonal responses in breast cancer patients. Journal of Steroid Biochemistry and Molecular Biology 79 115-125.
41. Shaulian E & Karin M 2001 AP-1 in cell proliferation and survival. Oncogene 20 2390-2400.
42. Shim WS, Conaway M, Masamura S, Yue W, Wang J-P, Kumar R & Santen RJ 2000 Estradiol hypersensitivity and mitogen-activated protein kinase expression in long-term estrogen deprived human breast cancer cells in vivo. Endocrinology 141 396-405.
43. Smith PJ, Wise LS, Berkowitz R, Wan C & Rubin CS 1988 Insulin-like growth factor-I is an essential regulator of the differentiation of 3T3-L1 adipocytes. Journal of Biological Chemistry 263 9402-9408.
44. Song RXD, Mor G, Naftolin F, McPherson RA, Song J, Zhang Z, Yue W, Wang J-P & Santen RJ 2001 Effect of long term oestrogen deprivation on apoptotic responses of breast cancer cells to 17β-estradiol. Journal of the National Cancer Institute 93 1714-1723.
45. Song RX, McPherson RA, Adam L, Bao Y, Shupnik M, Kumar R & Santen RJ 2002 Linkage of rapid estrogen action to MAPK activation by ERalpha-Shc association and She pathway activation. Molecular Endocrinology 16 116-127.
46. Song RX, Barnes CJ, Zhang Z, Bao Y, Kumar R & Santen RJ 2004 The role of She and insulin-like growth factor 1 receptor in mediating the translocation of estrogen receptor alpha to the plasma membrane. P N A S 101 2076-2081.
47. Song RX, Zhang Z, Mor G & Santen RJ 2005 Downregulation of Bcl-2 enhances estrogen apoptotic action in long-term estradiol-depleted ER+ breast cancer cells. Apoptosis 10 667-678.
48. Speirs V, Malone C, Walton DS, Kerin MJ & Atkin S 1999 Increased expression of estrogen receptor β mRNA in tamoxifen-resistant breast cancer patients. Cancer Research 59 5421-5424.
49. Stephen RL, Shaw LE, Larsen C, Corcoran D & Darbre PD 2001 Insulin-like growth factor receptor levels are regulated by cell density and by long-term estrogen deprivation in MCF-7 human breast cancer cells. Journal of Biological Chemistry 276 40080-40086.
50. Stewart AJ, Johnson MD, May FEB & Westley BR 1990a The role of IGFs and type I IGF receptor in the estrogen stimulated proliferation of human breast cancer cells. Journal of Biological Chemistry 265 21172-21178.
51. Stewart AJ, Johnson MD, May FE & Westley BR 1990b Role of insulin-like growth factors and the type I insulin-like growth factor receptor in the estrogen-stimulated proliferation of human breast cancer cells. Journal of Biological Chemistry 265 21172-21178.
52. Surmacz E & Burgaud JL 1995 Overexpression of insulin receptor substrate 1 (IRS-1) in the human breast cancer cell line MCF-7 induces loss of estrogen requirements for growth and transformation. Clinical Cancer Research 1 1429-1436.
53. Wakeling AE & Bowler J 1992 ICI 182,780, a new antiestrogen with clinical potential. Journal of Steroid Biochemistry and Molecular Biology 43 173-177.
54. Webb P, Nguyen P, Valentine C, Lopez GN, Kwok GR, McInerney E, Katzenellenbogen BS, Enmark E, Gustafsson JA, Nilsson S & Kushner PJ 1999 The estrogen receptor enhances AP-1 activity by two distinct mechanisms with different requirements for receptor transactivation functions. Molecular Endocrinology 13 1672-1685.